EU Joint Clinical Assessment enters second year as pharmaceutical companies adapt evidence strategies
- nuaxia
- il y a 5 jours
- 3 min de lecture
The EU Health Technology Assessment Regulation now requires eligible oncology medicines and advanced therapies to undergo a single European clinical assessment, increasing the importance of early evidence planning alongside EMA regulatory development.
The European Union’s Joint Clinical Assessment (JCA) framework has been operating since 12 January 2025 for new oncology medicines and advanced therapy medicinal products, requiring developers to submit evidence for a common EU-level assessment alongside the marketing authorisation process.
The system is changing market-access planning because developers must anticipate evidence requirements across Member States earlier, while national authorities retain responsibility for pricing, reimbursement, economic evaluation and other country-specific decisions.
Field | Content |
Alert Type | Industry Update |
Topic | Health technology assessment; market access; evidence generation |
Organisation(s) | European Commission; Member State Coordination Group on Health Technology Assessment (HTACG); European Medicines Agency (EMA); national HTA bodies |
Affected Stakeholders | Pharmaceutical and biotechnology companies developing oncology medicines and advanced therapies; market-access, HEOR, medical affairs and clinical-development teams; national HTA authorities |
Therapy Area(s) | Oncology; Advanced therapies |
Geography | European Union |
What Happened | The EU Health Technology Assessment Regulation has applied since 12 January 2025, initially requiring JCAs for new cancer medicines containing new active substances and advanced therapy medicinal products submitted through the centralised EMA procedure. Developers must provide clinical evidence for an EU-level assessment of the relative effects of their technology, with the resulting JCA report subsequently considered by Member States in their national HTA processes. In 2026, these product groups remain in scope, while selected medical devices are also expected to enter JCA. (Public Health) |
Why It Matters | JCA introduces a common European clinical evidence assessment but does not create a single EU reimbursement decision. Developers therefore need evidence packages capable of addressing the EU-level assessment while still preparing for national requirements covering issues such as cost-effectiveness, pricing and reimbursement. This increases the importance of coordinating regulatory, clinical-development, HEOR and market-access planning earlier in a product’s development. (Public Health) |
Supporting Context | JCA reports focus on clinical domains and do not make value judgements or reimbursement recommendations. National authorities must consider the JCA report but may supplement it with additional analyses required for their own decision-making. The framework is being introduced progressively: orphan medicines enter scope from 13 January 2028, followed by all other new centrally authorised medicines from 13 January 2030. (EUR-Lex) |
Who Is Most Affected | Developers of new oncology medicines and advanced therapies currently face the most immediate requirements, particularly teams responsible for clinical evidence generation, market access and HTA submissions. The impact will broaden substantially as orphan medicines and ultimately all new centrally authorised medicines enter the framework. (EUR-Lex) |
Industry Impact | JCA could reduce duplication of clinical assessments across European markets, but it also concentrates evidence requirements into an earlier and more coordinated process. For pharmaceutical companies, this makes early identification of relevant patient populations, comparators, endpoints and evidence gaps increasingly important when designing development programmes intended to support both regulatory approval and European market access. |
Key Takeaway | JCA is shifting European market-access planning upstream, requiring developers to consider EU-wide clinical evidence needs earlier while continuing to prepare for country-specific reimbursement assessments. |
What to Watch | The HTACG expects around 50 medicinal-product JCAs in 2026, providing a larger test of the framework’s operational capacity. Further experience with published assessments, the introduction of selected medical devices and preparations for orphan medicines entering scope in 2028 will show how the system develops beyond its initial implementation phase. (Public Health) |
Primary Source | |
Relevant Date | 12 January 2025 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires